Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Fernando Prados Roa, deputy minister of health for Madrid, discusses the health paradigm of the community and elaborates on the role of SERMAS in managing and coordinating the city’s public…
Baltasar Lobato, managing partner of health and life sciences at EY Spain, highlights the major market trends affecting the public and private healthcare sector as well as the pharmaceutical market.…
The global rich list is splattered with household names who have built their reputation not only through business acumen but through eye-catching purchases such as Steve Balmer’s record buyout of…
LEO Pharma’s Paolo Cionini discusses recent structural changes in the dermatology specialist’s Europe South operations, the importance of Spain to the regional group, and the nation’s digital capabilities. The…
Dr Sergi Trilla, CEO and founder of life sciences business development provider trifermed, introduces the company and explains its evolution to better serve the shifting paradigms of the healthcare and…
One of the unique aspects of the system is the fragmentation linked to the country’s 17 autonomous regions The Spanish healthcare system performance is ranked as 7th in the world…
Following Bayer’s acquisition of Monsanto, a US agriculture giant, the company is facing a new era in which its pharmaceutical arm is still a highly strategic part. Bernardo Kanahuati, Bayer’s…
Oriol Segarra, CEO of Uriach, describes the Spanish OTC company’s recent developments and transformation from a domestic organization to a truly European player. These are very interesting times for…
Francesc Posas, the newly appointed director of the Institute for Research in Biomedicine (IRB Barcelona), explains the evolving role of the institute as a bridge between basic research and concrete…
Madrid, Spain’s capital, is the city with the highest life expectancy in Europe at 85.2 years. Moreover, Spain as a whole is one of Europe’s best performers in terms of…
Enrique Ruiz Escudero, Minister of Health of the Community of Madrid, discusses his strategy to maintain Madrid’s spot as having Spain’s leading healthcare system, the creation of the bio-region –‘Biomad’,…
Ignacio Vega and Carlos Ibares Sanz of Spanish medtech Cardiva, explain the group’s origins as a distributor, the growing importance of manufacturing, and the company’s international ambitions. How has…
See our Cookie Privacy Policy Here
